Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Nanotech treatment gets boost with GSK licensing agreement

James R. Baker, Jr., M.D.
James R. Baker, Jr., M.D.

Abstract:
Pharmaceutical giant's partnership with U-M spinoff NanoBio marks major milestone in moving nanoemulsion technology to market

Nanotech treatment gets boost with GSK licensing agreement

Ann Arbor, MI | Posted on December 23rd, 2009

GlaxoSmithKline and Ann Arbor-based NanoBio Corporation announced today that they have signed an exclusive over-the-counter licensing agreement for NanoBio's unique nanoemulsion treatment for cold sores in the United States and Canada.

James R. Baker, Jr., M.D., director of the Michigan Nanotechnology Institute for Medicine and Biological Sciences at the University of Michigan Medical School, developed nanoemulsions in the 1990s at U-M and founded NanoBio Corporation to further develop and commercialize the technology.

The nanoemulsion technology is patented by U-M and licensed to NanoBio Corporation. Dr. Baker serves as CEO of NanoBio Corporation, where he holds a financial interest. At U-M, he also is the Ruth Dow Doan Professor of Internal Medicine and allergy division chief.

"For the university, this agreement between NanoBio and GlaxoSmithKline demonstrates the value of our technology and fulfills our goal of getting the benefits of our research deployed broadly to the general public," says Ken Nisbet, executive director of the U-M Office of Technology Transfer.

"We're very proud of the accomplishments of Dr. Baker and the entire NanoBio team."

Under the new agreement, New Jersey-based GlaxoSmithKline will pay NanoBio an up-front fee of $14.5 million for licensing rights for the nanoemulsion product called NB-001. NanoBio is eligible to receive additional milestone payments of up to $40 million plus high single-digit royalties on future sales.

Nanoemulsions are superfine mixtures of soybean oil and water, stabilized by surfactants and blended at very high speeds so that the resulting droplets are less than 400 nanometers in diameter. Nanoemulsion droplets fuse with a microbe's outer membrane, disrupt the membrane and kill the organism.

Baker believes that the GlaxoSmithKline-NanoBio partnership will "enable the development and commercialization of NB-001 to its fullest potential and validates the promise of our proprietary platform technology, and its potential use in a wide range of dermatological and anti-infective applications."

NB-001 is the first nanoemulsion therapeutic to complete successful phase 2 clinical trials and will enter phase 3 testing within the next six months. NanoBio is developing other nanoemulsion-based therapies for a range of diseases including fungal infections, acne and molluscum contagiosum.

Cold sores, caused by the virus herpes labialis, affect about one-fifth of adults in the United States. NB001 will add to GSK's Abreva line of over-the-counter medications for cold sores.

References:

More about the Michigan Nanotechnology Institute

nano.med.umich.edu

More about nanoemulsions

nano.med.umich.edu/Platforms/Antimicrobial-Nanoemulsion.html

More about the U-M Office of Technology Transfer

www.techtransfer.umich.edu/

####

About University of Michigan Health System
Excellence in medical education, patient care and research: That's what defines the University of Michigan Health System.

For more information, please click here

Contacts:
Media contact:
Anne Rueter

734-764-2220

Copyright © University of Michigan Health System

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014

UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014

Deadline Announced for Registration in 7th Int'l Nanotechnology Festival in Iran July 23rd, 2014

A Crystal Wedding in the Nanocosmos July 23rd, 2014

Nanomedicine

Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014

NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014

SentiMag® Now Available in Australia and New Zealand July 21st, 2014

More than glitter: Scientists explain how gold nanoparticles easily penetrate cells, making them useful for delivering drugs July 21st, 2014

Announcements

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014

UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014

Deadline Announced for Registration in 7th Int'l Nanotechnology Festival in Iran July 23rd, 2014

A Crystal Wedding in the Nanocosmos July 23rd, 2014

Patents/IP/Tech Transfer/Licensing

UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014

Bruker Awarded Fourth PeakForce Tapping Patent: AFM Mode Uniquely Combines Highest Resolution Imaging and Material Property Mapping July 22nd, 2014

Rice's silicon oxide memories catch manufacturers' eye: Use of porous silicon oxide reduces forming voltage, improves manufacturability July 10th, 2014

Using Sand to Improve Battery Performance: Researchers develop low cost, environmentally friendly way to produce sand-based lithium ion batteries that outperform standard by three times July 8th, 2014

Nanobiotechnology

Production of Non-Virus Nanocarriers with Highest Amount of Gene Delivery July 17th, 2014

Physicists Use Computer Models to Reveal Quantum Effects in Biological Oxygen Transport: The team solved a long-standing question by explaining why oxygen – and not deadly carbon monoxide – preferably binds to the proteins that transport it around the body. July 17th, 2014

Tiny DNA pyramids enter bacteria easily -- and deliver a deadly payload July 9th, 2014

Artificial cilia: Scientists from Kiel University develop nano-structured transportation system July 4th, 2014

Alliances/Partnerships/Distributorships

Organometallics welcomes new editor-in-chief: Paul Chirik, Ph.D. July 22nd, 2014

Haydale and Goodfellow Announce Major Distribution Agreement for Functionalised Graphene Materials July 21st, 2014

SentiMag® Now Available in Australia and New Zealand July 21st, 2014

Martini Tech Inc. becomes the exclusive distributor for Yoshioka Seiko Co. porous chucks for Europe and North America July 20th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE